Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ...

Nivolumab significantly improved median RFS and DMFS compared to ipilimumab in resected stage IIIB to IIIC or IV melanoma patients. The study suggested potential benefits of morning dosing, with ...

Nivolumab shows lasting melanoma recurrence prevention, with long-term safety, in largest-ever CheckMate 238 trial analysis.

The median duration of recurrence-free survival was 61.1 and 24.2 months with nivolumab and ipilimumab, respectively, at a minimum follow-up of 107 months.

A genetically engineered herpes virus may offer a new and effective treatment for advanced melanoma, providing hope for ...

The winner of a 2025 SITC grant examines mechanisms that may help explain why drugs that work for some forms of lymphoma ...

Immunotherapy against melanoma is more effective and has fewer side effects when administered in the morning. This is one of ...

Two therapies can be better than one for treating some cancers, concludes a Yale study published Oct. 22 in JCI Insight that ...

The efficacy of nivolumab plus ipilimumab compared with chemotherapy alone was evaluated through a meta-analysis, 1 using HRs to determine the efficacy. A random-effects model was utilized to pool all ...

Over the past decade, subcutaneous formulations of anticancer drugs—originally administered intravenously—have been ...